IN8bio (NASDAQ:INAB – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.
Analyst Recommendations
This is a summary of current ratings and target prices for IN8bio and OKYO Pharma, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
IN8bio | 0 | 0 | 2 | 0 | 3.00 |
OKYO Pharma | 0 | 0 | 1 | 0 | 3.00 |
IN8bio currently has a consensus target price of $6.75, suggesting a potential upside of 2,894.68%. OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 363.94%. Given IN8bio’s higher probable upside, equities research analysts plainly believe IN8bio is more favorable than OKYO Pharma.
Institutional & Insider Ownership
Valuation & Earnings
This table compares IN8bio and OKYO Pharma”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
IN8bio | N/A | N/A | -$30.01 million | ($0.58) | -0.39 |
OKYO Pharma | N/A | N/A | -$16.83 million | N/A | N/A |
Risk and Volatility
IN8bio has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.
Profitability
This table compares IN8bio and OKYO Pharma’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
IN8bio | N/A | -197.15% | -130.48% |
OKYO Pharma | N/A | N/A | N/A |
About IN8bio
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.